There are three other therapies (one a device) which are currently in Phase 3 in PWS. One is Acadia’s candidate, intranasal carbetocin, which I think also has a good chance of Phase 3 success and approval. The trial's primary outcome is in hyperphagia but this drug has previously been demonstrated to also improve anxiousness.
There are several Phase 2 studies ahead of us as well. Some are focused on hyperphagia and others on behaviour and excessive sleepiness.
So there may already be a range of other therapy options if and when NNZ-2591 in PWS comes to market.
PWS Clinical Trials (fpwr.org)
PHASE2 PRADER WILLI SYNDROME START !!!!, page-34
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.68 |
Change
-0.100(0.48%) |
Mkt cap ! $2.643B | |||
| Open | High | Low | Value | Volume |
| $20.50 | $20.74 | $20.01 | $5.091M | 247.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 156 | $20.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.68 | 256 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |